IM Dose - talk at ASH

[Guest guest]

Here¹s a short post on a talk that Australia¹s Tim gave on the TIDEL

(IM dose intensity) trial. I won¹t say that much about it because a lot of

the info isn¹t new, such as that patients on higher doses of IM reach the

various response levels faster, and that toxicity (mostly non-hematologic)

increases with higher doses.

In fact, the one new and interesting thing he had to say was in response to

a question: that is, whether they looked at the relationship between body

mass index and patient response to any given dose. They said that they did,

and could see no relationship. I believe Novartis concluded the same thing

in their original trials, but it was interesting to see it confirmed. I

still suspect that effective serum levels of IM may vary somewhat, and that

basing dose on serum level would be a good idea ­ but in any case, we can¹t

use body mass index as a means to guess the appropriate dose.

R